MF6 MagForce AG

MagForce AG Receives FDA Investigational Device Exemption Approval to Conduct a Clinical Trial with NanoTherm Therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer

BERLIN & CARSON CITY, Nev.--(BUSINESS WIRE)--

MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc., announces that it has received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to conduct a clinical trial with NanoTherm therapy as focal ablation treatment for intermediate risk prostate cancer.

The approval of this IDE now allows MagForce to conduct a pivotal clinical evaluation with the Company's innovative NanoTherm therapy at selected medical centers in the US. MagForce anticipates to initiate patient enrollment in this study in the coming months.

The purpose of this focal thermal ablation registration study that will enroll up to 120 men in a single arm study is to demonstrate that NanoTherm can focally ablate cancer lesions for patients who have advanced to intermediate risk prostate cancer stage and are under active surveillance. By focally ablating these cancer lesions, it is anticipated that patients will be able to be maintained in Active Surveillance Programs and to avoid definitive therapies such as surgery or whole gland radiation with their well-known side effects.

EN
10/02/2018

Underlying

MF6MagForce AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MagForce AG

Sean Conroy
  • Sean Conroy
MF6 MAGFORCE AG

MagForce - Termination of coverage

Edison Investment Research is terminating coverage on Mercia Asset Management (MERC), Bloc Ventures (unlisted), YOC (YOC.DE), Genuit Group (GEN), AlzeCure Pharma (ALZCUR), abrdn Latin American Income Fund (ALAI), Magforce (MF6), OPG Power Ventures (OPG) and paragon (PGN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

10/31/22 October 31, 2022 1 EN
Cosmin Filker
  • Cosmin Filker
MF6 MAGFORCE AG

Research Comment englisch - MagForce AG - 27.07.22

MagForce AG unexpectedly files for insolvency; price target and rating, suspended In an announcement dated 26.07.2022, MagForce AG informed the capital market, to our, complete surprise, that it intends to file for insolvency proceedings due to insolvency. According to the company's announcement, this had become necessary after reorganisationmeasures had not led to the desired cost savings. Even though the company has not yet been able to generate any significant cash inflows from its operatin...

07/28/22 July 28, 2022 4 EN
Cosmin Filker
  • Cosmin Filker
MF6 MAGFORCE AG

Research Comment - MagForce AG - 27.07.22

MagForce AG meldet überraschend Insolvenz an; Kursziel und Rating ausgesetzt Mit Meldung vom 26.07.2022 hat die MagForce AG den Kapitalmarkt, für uns komplett überraschend, darüber informiert, einen Antrag auf Eröffnung eines Insolvenzverfahrens wegen Zahlungsunfähigkeit stellen zu wollen. Gemäß Unternehmensmeldung sei dies notwendig geworden, nachdem reorganisatorische Maßnahmen nicht zu den gewünschten Kosteneinsparungen geführt haben. Auch wenn die Gesellschaft aufgrund der noch nicht erfol...

07/28/22 July 28, 2022 4 DE
Cosmin Filker
  • Cosmin Filker
MF6 MAGFORCE AG

Investment im Fokus - MagForce AG - 18.07.22

Die MagForce AG mit Sitz in Berlin ist nach eigenen Angaben ein führendes Unternehmen auf dem Gebiet der Nanomedizin mit Fokus auf der Krebstherapie. Die von ihr entwickelte NanoTherm® Therapie wäre nach Unternehmensangaben für die lokale Behandlung von nahezu allen soliden Tumoren geeignet. Die Behandlung erfolgt durch Wärme, die mittels Aktivierung von injizierten superparamagnetischen Nanopartikeln erzeugt wird. Die Bestandteile dieser Therapie, die Medizinprodukte NanoTherm®, NanoPlan®, Ther...

07/18/22 July 18, 2022 5 DE
Cosmin Filker ... (+2)
  • Cosmin Filker
  • Marcel Goldmann
MF6 MAGFORCE AG

Research Report (Anno) englisch - MagForce AG - 13.07.22

By its own account, MagForce AG, with its registered office in Berlin, is a leading company in the field of nanomedicine with a focus on cancer treatment. The NanoTherm® treatment developed by the company could be suitable for the local treatment of almost all solid tumours. The treatment is based on heat that is created by the activation of injected superparamagnetic nanoparticles. The components of this treatment, the medical devices NanoTherm® and NanoPlan® and the thermometric catheter TK01 ...

07/13/22 July 13, 2022 20 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch